Welcome to chemicalbook!
+1 (818) 612-2111
RFQ
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >ent-Ertugliflozin
ent-Ertugliflozin
  • ent-Ertugliflozin
  • ent-Ertugliflozin
  • ent-Ertugliflozin
  • ent-Ertugliflozin
  • ent-Ertugliflozin

ent-Ertugliflozin NEW

Price Get Latest Price
Package 10mg 50mg 100mg
Min. Order: 10mg
Supply Ability: 1000
Update Time: 2025-07-31

Product Details

Product Name: ent-Ertugliflozin CAS No.: 2242891-20-7
Min. Order: 10mg Purity: 99%+ HPLC
Supply Ability: 1000 Release date: 2025/07/31

ent-Ertugliflozin; 2222717-52-2

Article illustration


Product Information


  • English Name: ent-Ertugliflozin

  • English Alias: (1R,2R,3R,4S,5R)-5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol

  • CAS No.: 2242891-20-7

  • Molecular Formula: C₂₂H₂₅ClO₇

  • Molecular Weight: 436.88


Advantages


  • High Purity Guarantee: Confirmed by HPLC with a purity of ≥99.0%, and the structure is verified by NMR (1H, 13C), HRMS, and elemental analysis, providing a reliable basis for studies related to Ertugliflozin.

  • Good Stability: Stable for 36 months under storage conditions of -20℃ in the dark and sealed. The degradation rate is less than 0.2% in common solvents, ensuring good repeatability of experimental results.


Applications


  • Drug Research: Used as a reference substance for the separation study of Ertugliflozin enantiomers, facilitating the development of chiral drug analysis methods.

  • Quality Control: Used for the quality inspection of Ertugliflozin API and formulations, controlling the content of related impurities to ensure that the drug quality meets the standards.

  • Mechanism Exploration: In the study of drug action mechanisms, it helps analyze the metabolic differences and biological activity differences of its enantiomers in vivo.


Background Description
Ertugliflozin is a drug for treating type 2 diabetes, which reduces blood sugar by inhibiting renal glucose reabsorption. ent-Ertugliflozin, as its enantiomer, may be produced during the synthesis process. The presence of enantiomers may affect the pharmacokinetics, pharmacodynamics, and safety of the drug. With the in-depth research on chiral drugs, the study of ent-Ertugliflozin helps to comprehensively understand the properties of Ertugliflozin and ensure the safety and effectiveness of medication.


Research Status


  • Detection Technology: Supercritical fluid chromatography (SFC) - MS/MS or high-performance liquid chromatography with chiral columns are used to effectively separate ent-Ertugliflozin from Ertugliflozin, with a limit of detection of 0.002 ng/mL.

  • Activity Research: In vitro cell experiments show that the affinity of ent-Ertugliflozin for the SGLT2 receptor is lower than that of Ertugliflozin, and its hypoglycemic activity is weaker, but it may have other potential biological activities, and related research is ongoing.

  • Metabolism Research: Animal experiments have found that the metabolic pathways of ent-Ertugliflozin in vivo partially overlap with those of Ertugliflozin, but the metabolic rates and products are different, and the specific mechanisms remain to be further clarified.


WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com


NOTE!

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17320513646
E-mail: anna@molcoo.com


NEW IN STOCK!

The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery! 




Company Profile Introduction

-

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/1g
VIP2Y
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
2024-12-12
$0.00/5mg
VIP1Y
Guangzhou Tosun Pharmaceutical Ltd
2025-02-06
$0.00/10mg
VIP2Y
ShenZhen H&D Pharmaceutical Technology Co., LTD
2024-06-13
INQUIRY